HeyJaredN Engl J Med
- Indexed articles, last 90 days
- 5
- Latest publication
- Sep 29, 2026
- Outlet visibility, for Medscape
- Top 50K sites
- Earliest in this view
- Jul 6, 2026
Latest articles
Tambotatug Pelitecan Boosts Survival in Relapsed SCLC (opens the original)
Read excerpt
Tambotatug pelitecan, a new antibody-drug conjugate, significantly improved overall survival and progression-free survival (PFS) compared with topotecan as second-line therapy for relapsed extensive-stage small-cell lung cancer (SCLC) in a phase 3 trial conducted in China. Despite a lower overall rate of grade ≥ 3 adverse events, tambotatug pelitecan was not categorically safer than topotecan given its distinct toxicity profile, including a higher risk for interstitial lung disease/pneumonitis.
Blinatumomab Boosts EFS in Children With High-Risk B-ALL (opens the original)
Read excerpt
A phase 3 trial found that replacing two cycles of intensive chemotherapy with two cycles of blinatumomab significantly improved event-free survival (EFS) among children with newly diagnosed high-risk B-cell acute lymphoblastic leukemia (ALL). The estimated 4-year EFS rates were 83.0% among patients who received blinatumomab and 70.3% among those who continued receiving additional chemotherapy cycles. Blinatumomab was also associated with substantially reduced toxic effects, including treatment-
Short Antibiotic Course Noninferior in Orthopedic Infections (opens the original)
Read excerpt
In patients who had a local antibiotic carrier implanted during surgery for orthopedic infections, a short course (≤ 7 days) of postoperative systemic antibiotics was noninferior to a long course (≥ 4 weeks) in terms of the rate of definite treatment failure at 12 months. "In the current trial, a short course (≤ 7 days) of systemic antibiotics was noninferior to a long course (≥ 4 weeks) with regard to definite treatment failure at 12 months in patients who had undergone surgical management of b
Catheter Thrombolysis Cuts Risk in Pulmonary Embolism (opens the original)
Read excerpt
Among patients with intermediate-to high-risk pulmonary embolism (PE), catheter-directed thrombolysis with alteplase plus anticoagulation reduced the risk for the composite of death, recurrent PE, cardiorespiratory decompensation or collapse within 7 days compared with anticoagulation alone. "In patients with intermediate-high-risk acute pulmonary embolism, catheter-directed thrombolysis with alteplase plus anticoagulation therapy led to a lower risk of death from any cause, recurrent pulmonary
Functional Cure for Hepatitis B Is Now âAchievableâ (opens the original)
Read excerpt
The novel antisense oligonucleotide bepirovirsen targeting hepatitis B virus (HBV) transcripts holds promise of a functional cure, at least in the short term, according to phase 3 results from the twin B-Well 1 and B-Well 2 trials reported recently in The New England Journal of Medicine. One in 5 patients on the drug achieved a functional cure at week 72 after therapy discontinuation compared with zero placebo patients: in the B-Well 1 trial, 127 of 650 patients (20%) vs zero of 328 patients); i
Publishing over time
Last 90 days. Choose a month to open its work.
Recurring subjects
Named in the text we hold. One piece can cover several.
Audience
Top 50K sites
For Medscape, the outlet · Measured Aug 1, 2026
Website popularity band, not a count of readers or article views.
About this data
Counts cover the work we have indexed. Tone needs enough text and a confident classification. Excerpts and episode notes are not full articles or transcripts.
Identity or attribution wrong? Suggest a correction.